Tissue Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Tissue Diagnostics Market is Segmented by Product (Instruments and Reagents, and Consumables), Technology (Immunohistochemistry, In-Situ Hybridizations, Digital Pathology and Workflow Management, and Others), Application (Breast Cancer, Prostate Cancer, Gastric Cancer, and Other Cancers), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.

Tissue Diagnostics Industry Overview

Tissue Diagnostic Market Summary
Study Period: 2018 - 2028
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 5.5 %

Major Players

Tissue Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Tissue Diagnostics Market Analysis

The tissue diagnostics market is expected to register a CAGR of 5.5% over the forecast period.

COVID-19 had a strong impact on the growth of the market during the pandemic period. This is mainly due to the adoption of tissue diagnostics for the COVID-19 diagnosis. For instance, the published in the Journal of Pathology in March 2021 mentioned that analyses for the presence of SARS-CoV-2 in the tissue of COVID-19 patients were essential to improve the understanding of the disease pathophysiology for interpretation of diagnostics histopathological findings in autopsies, biopsies or surgical specimens and to assess the potential for occupational infectious hazard. The use of tissue diagnostics increased during the pandemic and thus impacted the market studied. The utilization of tissue diagnosis to analyze the condition of the infected patient is expected to drive the market's growth over the forecast period.

Tissue-based diagnostics serve as one of the most important techniques for cancer diagnosis. According to Cancer Facts and Figures 2022, published in January 2022 by the American Cancer Society, an estimated 1.9 million new cancer cases were diagnosed in 2022, among which prostate cancer was estimated to be 186,670, followed by 169,870 cases of lung cancer, and 144,490 cases of female breast cancer. The increased prevalence of cancer and the high burden of other chronic diseases increase the demand for accurate diagnosis and treatment. Moreover, with the rising burden of diseases caused by unhealthy lifestyles, such as obesity, being overweight is expected to drive market growth. Furthermore, the World Health Organization (WHO) published in 2021 that modifiable behavioral risk factors such as tobacco use account for over 7.2 million deaths yearly, and 1.6 million deaths annually can be attributed to insufficient physical activity. Thus, such unhealthy lifestyles lead to non-communicable diseases driving the demand for effective diagnostics, such as tissue diagnostics, during the forecast period.

Product launches by various key market players to meet the demand for effective diagnostics are also expected to drive the market's growth. For instance, in March 2021, the Quick-Core Auto Biopsy System ("Quick-Core Auto") for soft tissue biopsy was launched by IZI Medical Products LLC ("IZI"), a prominent developer of medical devices used in interventional radiology and interventional oncology treatments. The Quick-Core Auto is a lightweight, automatic biopsy equipment that adds to the reliability, precision, and quality of IZI's Quick-Core semi-automatic biopsy system.

Thus, the factors mentioned above, such as the growing burden of cancer and product launches, are expected to drive the market's growth during the forecast period. However, the high cost of diagnostics and reimbursement issues are expected to restrain the market's growth.

Tissue Diagnostics Industry Segments

As per the scope of the report, tissue diagnostics involves monitoring, diagnosis, and management of different stages of cancer.

The Tissue Diagnostics Market is Segmented by Product (Instruments and Reagents, and Consumables), Technology (Immunohistochemistry, In-Situ Hybridizations, Digital Pathology and Workflow Management, and Others), Application (Breast Cancer, Prostate Cancer, Gastric Cancer, and Other Cancers), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.

By Product
Instruments
Reagents and Consumables
By Technology
Immunohistochemistry
In-Situ Hybridization
Digital Pathology & Workflow Management
Other Technologies
By Application
Breast Cancer
Prostate Cancer
Gastric Cancer
Other Cancers
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Tissue Diagnostics Market Trends

This section covers the major market trends shaping the Tissue Diagnostics Market according to our research experts:

Breast Cancer Segment is Expected to Register a Significant Growth in the Forecast Years

The breast cancer segment holds a significant share of the market studied and is expected to follow the same trend over the forecast period. The main factor attributed to the growth of this segment is the increasing burden of breast cancer. As per Cancer Australia, in 2021, it was estimated that 20,030 new breast cancer cases were diagnosed in the country (164 males and 19,866 females). The same source reports that in 2021, a person had an estimated 1 in 15 (or 6.7%) risk of being diagnosed with breast cancer by the age of 85 (1 in 8 or 13% for females and 1 in 829 or 0.12% for males). Therefore, the high burden of breast cancer is increasing the demand for breast cancer treatment, thereby contributing to the market's growth.

According to the Centers for Disease Control and Prevention, in a November 2021 update, nearly 650,000 cancer patients (including breast cancer patients) receive chemotherapy every year in the United States. Hence, the increasing number of cancer cases and advancements in the field of tissue diagnostics are major factors contributing to the market's growth in the forecast period.

Additionally, product launches by the market are expected to support segment growth over the forecast period. For instance, in December 2021, Roche announced the debut of three new automated digital pathology algorithms for breast cancer, uPath Ki-67 (30-9), uPath ER (SP1), and uPath PR (1E2) image analysis, which are crucial indicators for breast cancer patients.

Thus, all factors above, such as the growing burden of breast cancer and product launches, are expected to boost the segment growth over the forecast period.

Tissue Diagnostics Market - Estimated Number of Breast Cancer Cases (in millions), By Sex, United States, 2022

North America holds the Largest Share in the Tissue Diagnostics Market During the Forecast Period.

The tissue diagnostics market holds the largest share in the North American region due to the increased awareness about the potential benefits of diagnostics among the population. The major factors driving the growth of the market in the United States include the well-established healthcare industry and the rising prevalence of cancer. According to statistics published by the Government of Canada and released in November 2021, about 229,200 Canadians were diagnosed with cancer in 2021. Prostate cancer was expected to remain the most diagnosed cancer, accounting for 46% of all cancer diagnoses in 2021. According to the same source, breast cancer affects one out of every eight women at some point in their lives. Such numbers indicate that the prevalence of cancer in the country is boosting the demand for tissue diagnostics in Canada.

The increasing product approvals by the US Food and Drug Administration (FDA) and subsequent launches, along with the high concentration of key players involved in research activities for the innovation of novel genetic testing products, are anticipated to drive market growth in North America. For instance, in May 2021, QIAGEN N.V. announced the expansion of companion tissue diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients who may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN).

Thus, all factors above, such as the growing prevalence of infections, will positively impact tissue diagnostics growth over the projected timeframe.

Tissue Diagnostics Market - Growth Rate by Region

Tissue Diagnostics Market Competitor Analysis

The tissue diagnostics market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies with significant market shares and are well-known. The global players in the tissue diagnostics market are Abbott Laboratories, Agilent Technologies, Inc., BioGenex Laboratories, Cancer Genetics, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Genomic Health, Inc., Merck KGaA and Thermo Fisher Scientific.

Tissue Diagnostics Market Top Players

  1. Abbott Laboratories

  2. Agilent Technologies, Inc.

  3. F. Hoffmann-La Roche Ltd

  4. Merck KGaA

  5. Thermo Fisher Scientific

*Disclaimer: Major Players sorted in no particular order

Tissue Diagnostics Market Concentration

Tissue Diagnostics Market Recent Developments

  • June 2022- F. Hoffmann La Roche announced the CE launch of the next-generation VENTANA DP 600 slide scanner. This high-capacity slide scanner produces excellent image quality of stained histology slides from patient tissue samples, which provides ease of use and workflow flexibility for the pathology lab.
  • March 2021- The Quick-Core Auto Biopsy System ("Quick-Core Auto") for soft tissue biopsy was launched by IZI Medical Products LLC ("IZI"), a prominent developer of medical devices used in interventional radiology and interventional oncology treatments. The Quick-Core Auto is a lightweight, automatic biopsy equipment that adds to the reliability, precision, and quality of IZI's Quick-Core semi-automatic biopsy system.

Tissue Diagnostics Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Cancer

      2. 4.2.2 Growing Healthcare Expenditure

      3. 4.2.3 Technological Advancements in Tissue Diagnostics

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Diagnosis and Reimbursement Issues

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value in USD Million)

    1. 5.1 By Product

      1. 5.1.1 Instruments

      2. 5.1.2 Reagents and Consumables

    2. 5.2 By Technology

      1. 5.2.1 Immunohistochemistry

      2. 5.2.2 In-Situ Hybridization

      3. 5.2.3 Digital Pathology & Workflow Management

      4. 5.2.4 Other Technologies

    3. 5.3 By Application

      1. 5.3.1 Breast Cancer

      2. 5.3.2 Prostate Cancer

      3. 5.3.3 Gastric Cancer

      4. 5.3.4 Other Cancers

    4. 5.4 By Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Agilent Technologies, Inc.

      3. 6.1.3 BioGenex Laboratories

      4. 6.1.4 Vyant Bio, Inc.

      5. 6.1.5 Danaher Corporation

      6. 6.1.6 F. Hoffmann-La Roche Ltd

      7. 6.1.7 Exact Sciences

      8. 6.1.8 Merck KGaA

      9. 6.1.9 Thermo Fisher Scientific

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Tissue Diagnostics Market Research FAQs

The Tissue Diagnostics Market market is studied from 2019 - 2027.

The Tissue Diagnostics Market is growing at a CAGR of 5.5% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott Laboratories, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific are the major companies operating in Tissue Diagnostics Market.

Tissue Diagnostics Industry Reports

In-depth industry statistics and market share insights of the Tissue Diagnostics sector for 2020, 2021, and 2022. The Tissue Diagnostics research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Tissue Diagnostics report PDF.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!